ÂÜŔňÂŇÂ×

Edmond Rambod is a transformational leader and a serial entrepreneur with more than 25 years of business, management and investment experience. Edmond’s focus has been on applications of technological innovations in medicine and value creation for the projects, companies and shareholders. Together with challenging the norms, Edmond’s strength is in the fusion of his disciplined management style and cross-functional multidisciplinary and transdisciplinary knowledge and experience, unrelenting and methodical approach in innovation and creating sustainable products and results in medtech and medical device fields. He is the founder, current Chairman and CEO of Quantason Medical, pioneering in the field of real-time, image-based, hybrid ultrasound and spectroscopy (IDUS™) for target acquisition and positioning. Quantason Medical has perfected the principal implementation of IDUS™ for breast screening and cancer prevention. Under Edmond’s leadership, Quantason Medical grew rapidly to become a scale-up startup. Edmond excelled in his fellowship training in Cardiothoracic Surgery at UCLA and Cedars-Sinai Medical Center prior to becoming a senior scientist at Caltech and serving in senior advisory capacities to several medical device and MedTech companies. Edmond is the founder of BioQuantetics, a California Corporation where the foundations of dual-mode ultrasound spectrography was developed, conceptually transforming the use of traditional ultrasound for targeted image-based medicine, screening and diagnosis. Edmond previously served as the Chief Scientific Officer of National Quality Care, Inc., a publicly traded company (NASDAQ: NQCI) where he co-invented the core technologies for extracorporeal renal and cardiac devices, sold to Fresenius Medical Care. Edmond is an expert on cardiac implantable devices and is the inventor of several medical technologies and devices including image-based dynamic ultrasound spectrography (IDUS™), wearable artificial kidney (WAK™) and wearable ultrafiltration device (WUD™). Most recently, Edmond served on the Board of Orbis Diagnostics, a New Zealand company where he helped developing the human-interface features of a new viral (i.e., SARS-COV-2) airport and airborne testing device. Edmond has raised nearly $75M capital investments and grants for his projects and companies. In 1994 he was awarded the prestigious Van Dyke Prize of the American Physical Society for outstanding contributions to better understanding of the implications of intracardiac flow patterns. Edmond has co-authored fifty awarded and pending patents, possesses transdisciplinary scientific and medical knowledge, has published his work in leading scientific and medical Journals and lectured in more than 100 national and International scientific, medical and business events. He obtained his engineering and medical degrees from Technion-Israel Institute of Technology in Haifa, Israel and his executive MBA from UCLA-University of California, Anderson School of Management at Los Angeles.

Bel Air, California, USA